Klick Health's recent acquisition of Oxford PharmaGenesis reflects that shift. “Clearly for a lot of reasons that have been ...

Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with mid-stage clinical data for a new shot covering 25 strains – five more than its current Prevnar 20 ...

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia – a digital ...

When pharmaphorum last spoke with MRM Health founder and CEO Sam Possemiers at JP Morgan, he told us about his company’s microbiome-based therapy for ulcerative colitis. At LSX USA in Boston last ...

As antibody-drug conjugates (ADCs) continue to establish themselves as a cornerstone of modern oncology, breakthrough ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...

The UK government has said it will accept all 44 recommendations made in a recently published report on using AI tools in the NHS, including continual monitoring after deployment. This morning, the ...

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments. In a new ...

This is not simply a broader role for Market Access. It is an emerging leadership capability for the healthcare business.

The governor of New York has said that rising cases of measles constitute a "statewide disaster emergency," the first such ...